Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 70-76, October 2007

Treatment of Pediatric IgA Nephropathy

  • Keith K. Lau

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to: Dr. Keith K. Lau, Department of Pediatrics, University of California, Davis, 2516 Stockton Boulevard, Sacramento, CA 95817, USA. Fax: (+1) 916–7340629
    • ,
  • Lavjay Butani

Department of Pediatrics, University of California, Davis, USA

Article Outline

IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of children progress to end-stage renal disease. It is now obvious that IgA nephropathy in children is not as benign as previously thought. Physicians who care for children with IgA nephropathy should be aware of this risk of progression to renal insufficiency and make treatment a priority. Strict attention should be given to modify any coexisting morbidities that may further predispose young patients to renal deterioration. The pharmacologic agents and therapeutic options used to manage this common disease are reviewed, and a recommended approach is presented. [Hong Kong J Nephrol 2007;9(2):70–6]

Key words:  chronic glomerulopathy , end-stage renal disease , pediatric IgA nephropathy

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Nair R , Walker PD . Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? . Kidney Int . 2006;69:1455–1458
  2. Michalk D , Waldherr R , Seelig HP , Weber HP , Scharer K . Idiopathic mesangial IgA-glomerulonephritis in childhood. Description of 19 pediatric cases and review of the literature . Eur J Pediatr . 1980;134:13–22
  3. Kher KK , Makker SP , Moorthy B . IgA nephropathy (Berger's disease) — a clinicopathologic study in children . Int J Pediatr Nephrol . 1983;4:11–18
  4. Wyatt RJ , Kritchevsky SB , Woodford SY , Miller PM , Roy S , Holland NH , et al.   IgA nephropathy: long-term prognosis for pediatric patients . J Pediatr . 1995;127:913–919
  5. Yoshikawa N , Ito H , Nakamura H . IgA nephropathy in children from Japan. Clinical and pathological features . Child Nephrol Urol . 1988–1989;9:191–199
  6. Hogg RJ , Silva FG , Wyatt RJ , Reisch JS , Argyle JC , Savino DA . Prognostic indicators in children with IgA nephropathy — report of the Southwest Pediatric Nephrology Study Group . Pediatr Nephrol . 1994;8:15–20
  7. Hastings MC , Delos Santos NM , Wyatt RJ . Renal survival in pediatric patients with IgA nephropathy . Pediatr Nephrol . 2007;22:317–318
  8. McEnery PT , McAdams AJ , West CD . Glomerular morphology, natural history and treatment of children with IgA-IgG mesangial nephropathy . Pe rspect Nephrol Hypertens . 1973;1(Pt 1):305–320
  9. Andreoli SP , Bergstein JM . Treatment of severe IgA nephropathy in children . Pediatr Nephrol . 1989;3:248–253
  10. Welch TR , Fryer C , Shely E , Witte DP , Quinlan M . Double-blind, controlled trial of short-term prednisone therap y in immunoglobulin A glomerulonephritis . J Pediatr . 1992;121:474–477
  11. Waldo FB , Alexander R , Wyatt RJ , Kohaut EC . Alternate-day prednisone therapy in children with IgA-associated nephritis . Am J Kidney Dis . 1989;13:55–60
  12. Yoshikawa N , Ito H , Sakai T , Takekoshi Y , Honda M , Awazu M , et al.   A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group . J Am Soc Nephrol . 1999;10:101–109
  13. Welch TR , McAdams AJ , Berry A . Rapidly progressive IgA nephropathy . Am J Dis Child . 1988;142:789–793
  14. Itami N , Akutsu Y , Kusunoki Y , Tochimaru H , Takekashi Y . Does methylprednisolone pulse therapy deteriorate the course of rapidly progressive IgA nephropathy? . Am J Dis Child . 1989;143:441–442
  15. Boobes Y , Baz M , Durand C , Jaber K , Goldstein P , Berland Y . Early start of intensive therapy in malignant form of IgA nephropathy . Nephron . 1990;54:351–353
  16. Niaudet P , Murcia I , Beaufils H , Broyer M , Habib R . Primary IgA nephropathies in children: prognosis and treatment . Adv Nephrol Necker Hosp . 1993;22:121–140
  17. Roccatello D , Ferro M , Coppo R , Mazzucco G , Quattrocchio G , Piccoli G . Treatment of rapidly progressive IgA nephropathy . Contrib Nephrol . 1995;111:177–182
  18. Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, et al. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy . Am J Nephrol . 2004;24:147–153
  19. Yagi K, Okada M, Yanagida H, Kuwajima H, Ikeda M, Sugimoto K, et al. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy . Clin Exp Nephrol . 2003;7:270–274
  20. Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, et al. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial . Clin Exp Nephrol . 2003;7:48–51
  21. Clive DM , Galvanek EG , Silva FG . Mesangial immunoglobulin A deposits in minimal change nephrotic syndrome: a report of an older patient and review of the literature . Am J Nephrol . 1990;10:31–36
  22. Sinniah R . Occurrence of mesangial IgA and IgM deposits in a control necropsy population . J Clin Pathol . 1983;36:276–279
  23. Nolin L , Courteau M . Management of IgA nephropathy: evidence-based recommendations . Kidney Int Suppl . 1999;70:S56–S62
  24. Wyatt RJ , Hogg RJ . Evidence-based assessment of treatment options for children with IgA nephropathies . Pediatr Nephrol . 2001;16:156–167
  25. Kanno Y , Okada H , Yamaji Y , Nakazato Y , Suzuki H . Angiotensin-converting enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation . QJM . 2005;98:199–203
  26. Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy . Hypertens Res . 2004;27:963–970
  27. Kim MJ , Song JH , Suh JH , Lee SW , Kim GA . Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy . Yonsei Med J . 2003;44:463–472
  28. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy . Am J Kidney Dis . 1999;33:851–856
  29. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy . Am J Kidney Dis . 2001;38:18–25
  30. Nakao N , Yoshimura A , Morita H , Takada M , Kayano T , Ideura T . Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial . Lancet . 2003;361:117–124
  31. Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, et al  CE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study . J Nephrol . 2006;19:508–514
  32. Epstein M . Aldosterone blockade: an emerging strategy for abrogating progressive renal disease . Am J Med . 2006;119:912–919
  33. Frisch G , Lin J , Rosenstock J , Markowitz G , D'Agati V , Radhakrishnan J , et al.   Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial . Nephrol Dial Transplant . 2005;20:2139–2145
  34. Tang S , Leung JC , Chan LY , Lui YH , Tang CS , Kan CH , et al.   Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy . Kidney Int . 2005;68:802–812
  35. Maes BD , Oyen R , Claes K , Evenepoel P , Kuypers D , Vanwalleghem J , et al.   Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study . Kidney Int . 2004;65:1842–1849
  36. Chen X , Chen P , Cai G , Wu J , Cui Y , Zhang Y , et al.   A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy . Zhonghua Yi Xue Za Zhi . 2002;82:796–801 [In Chinese]
  37. Wyatt R , Novak J , Gaber L , Lau K . Immunoglobulin A nephropathy and Henoch-Schonlein purpura nephritis . In:  Kher KK ,  Schnaper HW ,  Makker SP editor. Clinical Pediatric Nephrology . 2nd edition. Informa Healthcare; 2007;p. 213–221
  38. Katsumata Y , Hasegawa K , Hoshino K . Concomitant therapy with prednisolone and cyclophosphamide in 17 cases with IgA nephropathy . Nippon Jinzo Gakkai Shi . 1985;27:295–302
  39. Woo KT , Edmondson RP , Yap HK , Wu AY , Chiang GS , Lee EJ , et al.   Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis . Clin Nephrol . 1987;27:56–64
  40. Woo KT , Lee GS , Lau YK , Chiang GS , Lim CH . Effects of triple therapy in IgA nephritis: a follow-up study 5 years later . Clin Nephrol . 1991;36:60–66
  41. Ballardie FW , Roberts IS . Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy . J Am Soc Nephrol . 2002;13:142–148
  42. Lai KN , Lai FM , Li PK , Vallance-Owen J . Cyclosporin treatment of IgA nephropathy: a short term controlled trial . Br Med J (Clin Res Ed) . 1987;295:1165–1168
  43. Lou T , Wang C , Chen Z , Shi C , Tang H , Liu X , et al.   Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy . Nephrology (Carlton) . 2006;11:113–116
  44. Donadio JV , Bergstralh EJ , Offord KP , Spencer DC , Holley KE . A controlled trial of fish oil in IgA nephropathy . N Engl J Med . 1994;331:1194–1199
  45. Dillon JJ . Fish oil therapy for IgA nephropathy: efficacy and interstudy variability . J Am Soc Nephrol . 1997;8:1739–1744
  46. Hogg RJ , Lee J , Nardelli NA , Cattran D , Hirschman G , Julian BA . Multicenter placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group . J Am Soc Nephrol . 2003;14:751A
  47. Chan JC , Mahan JD , Trachtman H , Scheinman J , Flynn JT , Alon US , et al.   Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study . Pediatr Nephrol . 2003;18:1015–1019
  48. Yoshikawa N , Ito H . Combined therapy with prednisolone, azathioprine, heparinwarfarin, and dipyridamole for paediatric patients with severe IgA nephropathy — is it relevant for adult patients . Nephrol Dial Transplant . 1999;14:1097–1099
  49. Miura M , Endoh M , Nomoto Y , Sakai H . Long-term effect of urokinase therapy in IgA nephropathy . Clin Nephrol . 1989;32:209–216
  50. Tomino Y , Miura M , Suga T , Yagame M , Endoh M , Nomoto Y , et al.   Effects of a “single shot” of urokinase on fibrinolytic activities in patients with IgA nephropathy . Tokai J Exp Clin Med . 1984;9:43–47
  51. Watanabe T , Takahashi S , Nakajo S , Hamasaki M . Pathological improvement of IgA nephropathy and Henoch-Schonlein purpura nephritis with urokinase therapy . Acta Paediatr Jpn . 1996;38:622–628
  52. Chen X, Qiu Q, Tang L, Liu S, Cai G, Liu H, et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy . Nephrol Dial Transplant . 2004;19:852–857
  53. Sato M , Hotta O , Tomioka S , Horigome I , Chiba S , Miyazaki M , et al.   Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy . Nephron Clin Pract . 2003;93:137–145
  54. Xie Y , Nishi S , Ueno M , Imai N , Sakatsume M , Narita I , et al.   The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy . Kidney Int . 2003;63:1861–1867
  55. Kawasaki Y , Takano K , Suyama K , Isome M , Suzuki H , Sakuma H , et al.   Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy . Pediatr Nephrol . 2006;21:1701–1706
  56. Lau KK , Gaber LW , Delos Santos NM , Fisher KA , Grimes SJ , Wyatt RJ . Pediatric IgA nephropathy: clinical features at presentation and outcome for African-Americans and Caucasians . Clin Nephrol . 2004;62:167–172

PII: S1561-5413(08)60003-4

doi:10.1016/S1561-5413(08)60003-4

Hong Kong Journal of Nephrology
Volume 9, Issue 2 , Pages 70-76, October 2007

Article Tools